Milestone Pharmaceuticals Inc (MIST)
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on cardiovascular medicines in the United States and Canada. Its lead product, CARDAMYST (etripamil) nasal spray, is approved for use in adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia, where it is used to help restore normal heart rhythm. The company is also advancing etripamil in atrial fibrillation with rapid ventricular rate. Milestone has a licensing and collaboration arrangement with Corxel Pharmaceuticals related to the development and commercialization of etripamil. Founded in 2003, the company is headquartered in Montreal, Canada, and its common stock trades on NASDAQ under the symbol MIST.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MIST
|
$1.11
|
-9.1% Downside
|
Fair
|
$6.33
|
419.1% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-2.4x
|
4.6x
|
92.3x
|
160.5 M
|
117.7 M
|
46.1%
|
87.1%
|
-0.7
|
—
|
75.3%
|
